Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
暂无分享,去创建一个
[1] M. Koopmanschap,et al. Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making , 2013, PharmacoEconomics.
[2] Isao Kamae,et al. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[3] M. Vray,et al. Évaluation médico-économique des produits de santé. Méthodologie pour la définition d’un impact significatif sur les dépenses de l’Assurance maladie et choix des référentiels pour l’interprétation des résultats , 2014 .
[4] A. Towse,et al. National Institute for Clinical Excellence (NICE): Is Economic Appraisal Working? , 2012, PharmacoEconomics.
[5] Steve Morgan,et al. Centralized drug review processes: are they fair? , 2006, Social science & medicine.
[6] Mark Nuijten,et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[7] N. Devlin,et al. Operationalizing Value-Based Pricing of Medicines , 2012, PharmacoEconomics.
[8] M. Drummond,et al. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment , 2010, The European Journal of Health Economics.
[9] Hodgkin Lymphoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .
[10] B. Falissard,et al. Current process and future path for health economic assessment of pharmaceuticals in France , 2015, Journal of market access & health policy.
[11] C. Lucioni,et al. Spending on pharmaceuticals in Italy: macro constraints with local autonomy. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[12] M. Weinstein,et al. QALYs: the basics. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] C. Carroll,et al. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis. , 2011, Health technology assessment.
[14] M. Koopmanschap,et al. SIMILARITIES AND DIFFERENCES BETWEEN FIVE EUROPEAN DRUG REIMBURSEMENT SYSTEMS , 2012, International Journal of Technology Assessment in Health Care.
[15] Jing Jing Li,et al. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. , 2009, JAMA.
[16] A. Stevens,et al. HTA responses and the classic HTA report. , 2003, Journal of public health medicine.
[17] Hilda Bastian,et al. Die Entwicklung von Gesundheitsinformationen unter Beteiligung von Bürgerinnen und Bürgern am Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). , 2011 .
[18] P. Littlejohns,et al. The National Institute for Health and Clinical Excellence and Its Role in Assessing the Value of New Cancer Treatments in England and Wales , 2011, Clinical Cancer Research.
[19] C. Mitton,et al. Priority setting in the provincial health services authority: survey of key decision makers , 2007, BMC Health Services Research.
[20] Lawrence D. Phillips,et al. Is quantitative benefit-risk modelling of drugs desirable or possible? , 2011, Drug discovery today. Technologies.
[21] C. Donaldson,et al. The New Myth , 2012, PharmacoEconomics.
[22] A. Dhar,et al. National Institute for Health and Clinical Excellence , 2005 .
[23] G. Priol,et al. What criteria for pharmaceuticals reimbursement? , 2003, The European Journal of Health Economics.
[24] Steve Morgan,et al. The Common Drug Review: a NICE start for Canada? , 2006, Health policy.
[25] T. Philipson,et al. Endogenous cost-effectiveness analysis and health care technology adoption. , 2013, Journal of health economics.
[26] J. Belsey,et al. Addressing the health technology assessment of biosimilar pharmaceuticals , 2010, Current medical research and opinion.
[27] Thomas Mittendorf,et al. Methods for determining cost-benefit ratios for pharmaceuticals in Germany , 2007, The European Journal of Health Economics.
[28] S. Simoens. Use of Economic Evaluation in Decision Making , 2010, Drugs.
[29] M. Alajarin,et al. General Methods , 2008 .
[30] L. Mantovani,et al. Guidelines for Economic Evaluations in Italy: Recommendations from The Italian Group of Pharmacoeconomic Studies , 2001 .
[31] A. Culyer,et al. NICE's social value judgements about equity in health and health care , 2012, Health Economics, Policy and Law.
[32] Kalipso Chalkidou,et al. Evidence and values: paying for end-of-life drugs in the British NHS , 2012, Health Economics, Policy and Law.
[33] N. Samani,et al. QALYs in cost-effectiveness analysis: an overview for cardiologists , 2015, Heart.
[34] Norman Daniels,et al. Decisions about access to health care and accountability for reasonableness , 1999, Journal of Urban Health.
[35] K. Marsh,et al. Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature , 2014, PharmacoEconomics.
[36] Panos Kanavos,et al. The impact of health technology assessments: an international comparison , 2010 .
[37] David Barnett,et al. Pharmacoeconomics: NICE's approach to decision-making. , 2010, British journal of clinical pharmacology.
[38] A. Anell. Priority setting for pharmaceuticals , 2004, The European Journal of Health Economics, formerly: HEPAC.
[39] M. Willis,et al. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden , 2010, The European Journal of Health Economics.
[40] Steven Simoens,et al. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? , 2012, Orphanet Journal of Rare Diseases.
[41] C. Mitton,et al. Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom. , 2006, Health affairs.
[42] Anthony J Culyer,et al. National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.
[43] J. Calltorp,et al. Priority setting in health policy in Sweden and a comparison with Norway. , 1999, Health policy.
[44] F. Antoñanzas. Challenges to achieving value in drug spending in a decentralized country: the Spanish case. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[45] M. Buxton. Implications of the appraisal function of the National Institute for Clinical Excellence (NICE). , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[46] Anton Berns,et al. Separating the wheat from the chaff , 1991, Current Biology.
[47] Uwe Siebert,et al. Methods, procedures, and contextual characteristics of health technology assessment and health policy decision making: Comparison of health technology assessment agencies in Germany, United Kingdom, France, and Sweden , 2009, International Journal of Technology Assessment in Health Care.
[48] A. Kilcoyne,et al. The Institute for Quality and Efficiency in Health Care , 2013 .
[49] W. Rogowski,et al. Clearing up the hazy road from bench to bedside: A framework for integrating the fourth hurdle into translational medicine , 2008, BMC health services research.
[50] E. Tacconelli. Systematic reviews: CRD's guidance for undertaking reviews in health care , 2010 .
[51] Katharina E. Fischer,et al. Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes , 2012, BMC Medical Informatics and Decision Making.
[52] B. Falissard,et al. Current Process and Future Path for Health Economic Assessment of Pharmaceuticals in France. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[53] B. Corbacho,et al. Health economic decision-making: a comparison between UK and Spain. , 2012, British medical bulletin.
[54] R. Busse,et al. Methods for the comparative evaluation of pharmaceuticals , 2005, GMS health technology assessment.
[55] L. Shaw,et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.
[56] Dana Goldman,et al. Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA. , 2010, Health economics.
[57] Nancy J Devlin,et al. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making. , 2006, Health policy.
[58] B. Bégaud,et al. How innovative are pharmaceutical innovations?: the case of medicines financed through add-on payments outside of the French DRG-based hospital payment system. , 2012, Health Policy.
[59] Panos Kanavos,et al. Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions. , 2012, Health policy.
[60] M. Koopmanschap,et al. EUROPEAN DRUG REIMBURSEMENT SYSTEMS' LEGITIMACY: FIVE-COUNTRY COMPARISON AND POLICY TOOL , 2012, International Journal of Technology Assessment in Health Care.
[61] A. Levy,et al. Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven? , 2006, PharmacoEconomics (Auckland).
[62] M. Cowie. National Institute for Health and Care Excellence. , 2015, European heart journal.
[63] Karl Claxton,et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. , 2015, Health technology assessment.
[64] H. Banta,et al. Public health services and cost-effectiveness analysis. , 2008, Annual review of public health.
[65] Deciding subsidy for pharmaceuticals based on ambiguous evidence. , 2008, Journal of health organization and management.
[66] Paul Hansen,et al. Health technology prioritization: which criteria for prioritizing new technologies and what are their relative weights? , 2011, Health policy.
[67] J. Krell,et al. The cost of a QALY. , 2010, QJM : monthly journal of the Association of Physicians.
[68] Jon Sussex,et al. Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches , 2011 .
[69] P. Kanavos,et al. Critique of the American Society of Clinical Oncology Value Assessment Framework for Cancer Treatments: Putting Methodologic Robustness First. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] F. Schubert. HEALTH TECHNOLOGY ASSESSMENT , 2002, International Journal of Technology Assessment in Health Care.
[71] David Parkin,et al. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.
[72] Belen Corbacho,et al. Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[73] J. Huisman. The Netherlands , 1996, The Lancet.
[74] M. Mckee,et al. The politics of health technology assessment in Poland. , 2012, Health policy.
[75] G. Priol,et al. What criteria for pharmaceuticals reimbursement? An empirical analysis of the evaluation of "medical service rendered" by reimbursable drugs in France. , 2003, The European journal of health economics : HEPAC : health economics in prevention and care.
[76] Martin Hoyle,et al. Historical lifetimes of drugs in England: application to value of information and cost-effectiveness analyses. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[77] Joshua A Hirsch,et al. Facts, fallacies, and politics of comparative effectiveness research: Part 2 - implications for interventional pain management. , 2010, Pain physician.
[78] F. Dionne,et al. Decision maker views on priority setting in the Vancouver Island Health Authority , 2008, Cost effectiveness and resource allocation : C/E.
[79] D. Banta. The development of health technology assessment. , 2003, Health policy.
[80] Aris Angelis,et al. Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment , 2016, PharmacoEconomics.
[81] M. Piccart,et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[82] M. Postma,et al. Quantification of the potential impact of cost-effectiveness thresholds on dutch drug expenditures using retrospective analysis. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[83] J. Dettori,et al. Health technology assessment , 2009, International Journal of Technology Assessment in Health Care.
[84] Adam P Dicker,et al. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] M. Piccart,et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[86] M. Drummond,et al. Differences among formulary submission guidelines: Implications for health technology assessment , 2011, International Journal of Technology Assessment in Health Care.
[87] E. Nicod,et al. Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study. , 2016, Health policy.
[88] F. Nilsson,et al. Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness , 2015, PharmacoEconomics.
[89] C. Dirksen,et al. Integrating evidence on patient preferences in healthcare policy decisions: protocol of the patient-VIP study , 2013, Implementation Science.
[90] Maarten J. IJzerman,et al. Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[91] Clare McGrath,et al. Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems) , 2006, International Journal of Technology Assessment in Health Care.
[92] N. Kenny,et al. An Ethical Analysis of International Health Priority-Setting , 2008, Health Care Analysis.
[93] A. Anell. Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees. , 2004, The European journal of health economics : HEPAC : health economics in prevention and care.
[94] J. Moisan,et al. Inter-provincial variation in government drug formularies. , 2001, Canadian journal of public health = Revue canadienne de sante publique.
[95] James Raftery,et al. Commentary: A clinical challenge , 2006, BMJ : British Medical Journal.